<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MITOXANTRONE HYDROCHLORIDE</span><br/>(mi-tox'an-trone)<br/><span class="topboxtradename">Novantrone<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antibiotic</span>; <span class="classification">immunosuppressant</span><br/><b>Prototype: </b>Doxorubicin<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Noncell-cycle specific antitumor agent with less cardiotoxicity than doxorubicin. Interferes with DNA synthesis by intercalating
         with the DNA double helix, blocking effective DNA and RNA transcription.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Highly destructive to rapidly proliferating cells in all stages of cell division.</p>
<h1><a name="uses">Uses</a></h1>
<p>In combination with other drugs for the treatment of acute nonlymphocytic leukemia (ANLL) in adults, bone pain in advanced
         prostate cancer. Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary progressive,
         progressive relapsing, or worsening relapsing-remitting multiple sclerosis.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Breast cancer, refractory lymphomas.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to mitoxantrone; myelosuppression; pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Impaired cardiac function; impaired liver and kidney function; systemic infections.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Combination Therapy for ANLL</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Induction Therapy:</span> 12 mg/m<sup>2</sup>/d on days 13, may need to repeat induction course. <span class="rdroute">IV Consolidation Therapy:</span> 12 mg/m<sup>2</sup> on days 1 and 2 (max: lifetime dose 80120 mg/m<sup>2</sup>)<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 833 mg/m<sup>2</sup> q34wk<br/><br/><span class="indicationtitle">Solid Tumors</span><br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 58 mg/m<sup>2</sup> once a week or 1820 mg/m<sup>2</sup> q34wk<br/><br/><span class="indicationtitle">Multiple Sclerosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 12 mg/m<sup>2</sup> over 515 min q3mo (max: lifetime dose 140 mg/m<sup>2</sup>)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>If mitoxantrone touches skin, wash immediately with copious amounts of warm water.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Withdraw contents of vial and add to at least 50 mL of D5W or NS. Use of goggles, gloves, and protective gown during drug
                  preparation and administration.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Give into the tubing as a freely running IV of D5W or NS and infused over at least 3 min or longer (i.e., 3060 min)
                  depending on the total volume of IV solution. If extravasation occurs, stop infusion and immediately restart in another vein.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Heparin, hydrocortisone, paclitaxel.</b>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B cholesteryl complex, aztreonam, doxorubicin liposome, paclitaxel, piperacillin/tazobactam, propofol, TPN.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Discard unused portions of diluted solution.</li>
<li>Once opened, multiple-use vials may be stored refrigerated at 2°8° C (35°46° F) for 14 d.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Arrhythmias, decreased left ventricular function, <span class="speceff-both">CHF</span>, tachycardia, ECG changes, <span class="speceff-life">MI</span> (occurs with cumulative doses of &gt;80100 mg/m<sup>2</sup>), edema, <span class="speceff-life">increased risk of cardiotoxicity</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting,</span> diarrhea, <span class="speceff-life">hepatotoxicity</span>. <span class="typehead">Hematologic:</span>
<span class="speceff-both">Leukopenia, thrombocytopenia</span>. <span class="typehead">Other:</span> Discolors urine and sclera a blue-green color. <span class="typehead"> Skin:</span>  Mild phlebitis, blue skin discoloration, alopecia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May impair immune response to <span class="classification">vaccines</span> such as influenza and pneumococcal infections. May have increased risk of infection with <b>yellow fever vaccine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> Rapidly taken up by tissues and slowly released into plasma, resulting in low renal, hepatic, and metabolic clearance rates;
      95% protein bound. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in bile. <span class="typehead">Half-Life:</span> 37 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor IV insertion site. Transient blue skin discoloration may occur at site if extravasation has occurred.</li>
<li>Monitor cardiac functioning throughout course of therapy; report signs and symptoms of CHF or cardiac arrhythmias.</li>
<li>Lab tests: Perform liver function tests prior to and during course of treatment. Monitor serum uric acid levels and initiate
            hypouricemic therapy before antileukemic therapy. Monitor carefully CBC with differential prior to and during therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Understand potential adverse effects of mitoxantrone therapy.</li>
<li>Expect urine to turn blue-green for 24 h after drug administration; sclera may also take on a bluish color.</li>
<li>Be aware that stomatitis/mucositis may occur within 1 wk of therapy.</li>
<li>Do not to risk exposure to those with known infections during the periods of myelosuppression.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>